BACKGROUND & AIMS: Celiac disease (CD) is associated with an increased risk of lymphoma. However, relatively few studies have assessed the outcome of patients diagnosed with both CD and lymphoma. We evaluated the temporal association between lymphoma and CD, along with clinical presentation, response to therapy, and prognosis. METHODS: Patients diagnosed with both CD and lymphoma were identified retrospectively in a tertiary referral center. Clinical characteristics and survival were analyzed. RESULTS: Sixty-three patients (36 men) were identified who had been diagnosed with lymphoma and CD. Thirty-six (57%) were diagnosed with CD before they were diagnosed with lymphoma. The most common histologic entity was diffuse, large, B-cell lymphoma, which affected 18 (29%) patients. Complete information for staging was available in 59 patients; 24 (38%) had stage IV disease. Only chemotherapy or only radiation therapy was used for 43 (68%) and 11 (17%) patients, respectively. The 5- and 10-year cumulative survival rates for the entire cohort were 58% and 39%, respectively. Survival of patients with T-cell lymphoma was shorter than for all other lymphomas (119.4 vs 22.8 mo; P = .02). CONCLUSIONS: CD is associated with B- and T-cell lymphomas. Patients with B-cell lymphomas had a better prognosis than those with T-cell lymphoma. Therapy is unsatisfactory for enteropathy-type T-cell lymphoma.
BACKGROUND & AIMS:Celiac disease (CD) is associated with an increased risk of lymphoma. However, relatively few studies have assessed the outcome of patients diagnosed with both CD and lymphoma. We evaluated the temporal association between lymphoma and CD, along with clinical presentation, response to therapy, and prognosis. METHODS:Patients diagnosed with both CD and lymphoma were identified retrospectively in a tertiary referral center. Clinical characteristics and survival were analyzed. RESULTS: Sixty-three patients (36 men) were identified who had been diagnosed with lymphoma and CD. Thirty-six (57%) were diagnosed with CD before they were diagnosed with lymphoma. The most common histologic entity was diffuse, large, B-cell lymphoma, which affected 18 (29%) patients. Complete information for staging was available in 59 patients; 24 (38%) had stage IV disease. Only chemotherapy or only radiation therapy was used for 43 (68%) and 11 (17%) patients, respectively. The 5- and 10-year cumulative survival rates for the entire cohort were 58% and 39%, respectively. Survival of patients with T-cell lymphoma was shorter than for all other lymphomas (119.4 vs 22.8 mo; P = .02). CONCLUSIONS:CD is associated with B- and T-cell lymphomas. Patients with B-cell lymphomas had a better prognosis than those with T-cell lymphoma. Therapy is unsatisfactory for enteropathy-type T-cell lymphoma.
Authors: Andreas Zettl; German Ott; Angela Makulik; Tiemo Katzenberger; Petr Starostik; Thorsten Eichler; Bernhard Puppe; Martin Bentz; Hans Konrad Müller-Hermelink; Andreas Chott Journal: Am J Pathol Date: 2002-11 Impact factor: 4.307
Authors: Alberto Rubio-Tapia; Mussarat W Rahim; Jacalyn A See; Brian D Lahr; Tsung-Teh Wu; Joseph A Murray Journal: Am J Gastroenterol Date: 2010-02-09 Impact factor: 10.864
Authors: C Cellier; E Delabesse; C Helmer; N Patey; C Matuchansky; B Jabri; E Macintyre; N Cerf-Bensussan; N Brousse Journal: Lancet Date: 2000-07-15 Impact factor: 79.321
Authors: Alessio Fasano; Irene Berti; Tania Gerarduzzi; Tarcisio Not; Richard B Colletti; Sandro Drago; Yoram Elitsur; Peter H R Green; Stefano Guandalini; Ivor D Hill; Michelle Pietzak; Alessandro Ventura; Mary Thorpe; Debbie Kryszak; Fabiola Fornaroli; Steven S Wasserman; Joseph A Murray; Karoly Horvath Journal: Arch Intern Med Date: 2003-02-10
Authors: Joseph A Murray; Carol Van Dyke; Matthew F Plevak; Ross A Dierkhising; Alan R Zinsmeister; L Joseph Melton Journal: Clin Gastroenterol Hepatol Date: 2003-01 Impact factor: 11.382
Authors: Markku Mäki; Kirsi Mustalahti; Jorma Kokkonen; Petri Kulmala; Mila Haapalahti; Tuomo Karttunen; Jorma Ilonen; Kaija Laurila; Ingrid Dahlbom; Tony Hansson; Peter Höpfl; Mikael Knip Journal: N Engl J Med Date: 2003-06-19 Impact factor: 91.245
Authors: A Rubio-Tapia; G Malamut; W H M Verbeek; R L J van Wanrooij; D A Leffler; S I Niveloni; C Arguelles-Grande; B D Lahr; A R Zinsmeister; J A Murray; C P Kelly; J C Bai; P H Green; S Daum; C J J Mulder; C Cellier Journal: Aliment Pharmacol Ther Date: 2016-08-03 Impact factor: 8.171
Authors: Jonas F Ludvigsson; Benjamin Lebwohl; Alberto Rubio-Tapia; Joseph A Murray; Peter H R Green; Anders Ekbom; Fredrik Granath Journal: Eur J Epidemiol Date: 2013-03-05 Impact factor: 8.082
Authors: John Jacob Kinross-Wright; Kalyan Chakravarthy Potu; Brandy Pownell; Randall Lamfers; Jonathan S Bleeker Journal: Case Rep Hematol Date: 2018-03-05